Onkologie. 2013:7(1):53-55

The benefits versus toxicity of temozolomide in patients with glioblastoma

Kateřina Zycháčková, Markéta Pospíšková, Milan Kohoutek, Michal Filip, Alena Jakšičová, Michal Zycháček
KOC KNTB a.s. Zlín

Primary brain tumors are a heterogeneous disease. The most important is glioblastoma multiforme, which constitutes 75 % of the high

grade gliomas. These are aggressive tumors with limited therapeutic options and poor prognosis. Median survival from diagnosis is 4,6

months without treatment in the management of around 12 months. The gold standard therapy today is radical surgery, chemoradiotherapy

followed by adjuvant chemotherapy with temozolomide. In our work we focus on the benefit of adding temozolomide to standard

radiotherapy compared with its toxicity.

Keywords: temozolomide, globlastoma multiforme, MGMT methylation, chemoradiation, chemotherapy

Published: February 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zycháčková K, Pospíšková M, Kohoutek M, Filip M, Jakšičová A, Zycháček M. The benefits versus toxicity of temozolomide in patients with glioblastoma. Onkologie. 2013;7(1):53-55.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-996. Go to original source... Go to PubMed...
    2. Stupp R, Hegi ME, Mason WP, et al. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC- NCIC trial. Lancet Oncol 2009; 10(5): 459-466. Go to original source... Go to PubMed...
    3. NCCN Clinical Practice Guidelines in Oncology v 1. 2010. Dostupne z http://www.nccn.org/index.asp.
    4. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl CancerInst 1993; 85(9): 704-710. Go to original source... Go to PubMed...
    5. Laws ER, Parney IF, Huang W, et al. Glioma Outcomes Investigators. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003; 99(3): 467-473. Go to original source... Go to PubMed...
    6. Hentschel SJ, Sawaya R. Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control 2003; 10(2): 190-214. Go to original source... Go to PubMed...
    7. Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in elderly. Cancer 2003; 97(3): 657-662. Go to original source... Go to PubMed...
    8. Lakomý R, Fadrus P, Šlampa P, Svoboda T, et al. Výsledky multimodální léčby glioblastomu multiforme: Konsekutivní série 86 pacientů diagnostikovaných v letech 2003-2009. Klinická Onkologie 2011; 24(2): 112-120.
    9. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substatiates the predictive value of O-6-Methylquanine-DNA methyltransferae promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10(6a): 1871-187. Go to original source... Go to PubMed...
    10. Filip M, Paleček T, Starý M, Lipina R, Mrůzek M, Školoudík D, Bár M, Hoffer R, Černý D, Doležilová V. Ultrazvukový peroperační monitoring glioblastomů v 2D obraze a reálném čase. Čes. a Slov. Neurol. a Neurochir. 2004; 67/100, 1: 42-47.
    11. Filip M, Linzer P, Šámal F. Peroperační 3D sonografie v neurochirurgii. Neurol. pro praxi 2010; 11(6): 415-417.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.